Digital mental health interventions for children are developing rapidly, yet a persistent gap remains between demonstrating that they work and making them available to families in routine care. This article ...
Un nouveau document d’orientation issu des projets ODIN et ODIN Mpox a été publié dans Open Access Government. Intitulé « De la surveillance aux systèmes : développer la génomique environnementale pour ...
A new policy paper from the ODIN and ODIN Mpox projects has been published in Open Access Government. “From Surveillance to Systems: Scaling Environmental Genomics for Epidemic Preparedness in ...
Informed consent is considered to be the standard method for respecting the autonomy of individual participants in research and practices and is thought to be based on several conditions: (1) ...
India has the highest number of HIV infected persons in the world after South Africa. Much HIV related behavioral, clinical and laboratory based research is ongoing in India. Yet little ...
In June 2025, CEPI convened a global consultation on Mpox CoP, bringing together experts to identify evidence gaps and advance licensure pathways for mpox subunit or RNA vaccines through assay harmonization, human studies, pre-clinical models, immunogenicity data, and regulatory engagement. Read more
As CEPI activates its highest-level response to the Bundibugyo Ebola emergency in DRC and Uganda, we mapped Africa's Phase 1 trial capacity. 45 institutions across 17 countries responded. Explore the full Summary Report and searchable site database here: Read more
Clinical trials of vaccines for high-mortality pathogens (such as Nipah and Ebola) during outbreaks face significant methodological and ethical challenges. This paper examines key ethical issues in such outbreak clinical trial designs. Read more
CEPI has developed a guidance document defining key Phase 1 elements to harmonize safety and immunogenicity assessment, enable comparability across candidates, support dose selection, and accelerate progression to Phase 2/3 during outbreaks, while ensuring ICH-GCP compliance. Read more
CEPI has announced a funding opportunity to develop innovative analytical technologies for vaccines. The goal is to reduce vaccine development, manufacturing, and release times; lower costs, improve equitable deployment in Low to Middle-Income Countries, and enhance analytical insights for vaccines. Read more
Proposed projects will be expected to increase regulatory and research ethics oversight capacity of national and regional authorities in SSA to operate at WHO maturity level 3 for clinical trial, registration and/or PV for medical products (therapeutics/vaccines) Read more
Resources
In collaboration with TGHN, CEPI created this playbook to bring together the many tools, resources and materials generated for pandemic preparedness and response from the COVID-19 pandemic. The first (Regulatory) chapter is now available.
TRANSVAC Academy offers training modules in vaccine R&D including grant management, statistics, cytometry and advanced process development. CEPI funded scholarships are provided to selected applicants from LMICs.
SPEAC is a CEPI and Brighton Collaboration project. SPEAC provides vaccine safety tools, resources, and expertise throughout the vaccine development process to enhance safety and build confidence in vaccines.
Monitoring Vaccine Performance against SARS CoV-2 Variants
The IVAC COVID-19 Vaccine Effectiveness Project (a CEPI- funded global systematic review which also includes neutralization capacity) outputs are publicly available on VIEWhub to assist all policy makers
International Pandemic Preparedness Secretariat
The IPPS serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission, across vaccines, therapeutics, and diagnostics. It performs a global annual progress review related to the 100 DM which feeds into implementation reports.
Vaccine Development
Process Maps
The UK Vaccine R&D Network has developed vaccine development maps to show key stages in human and veterinary vaccines development up to Phase III clinical trials. These process maps and associated case studies provide support in understanding key stages in vaccine development and where bottlenecks could cause delays.
